SCHEMBL23218363

SCHEMBL23218363

CCOC(=O)Cc1ccccc1OCc1cccc2oc(-c3ccnc(C#N)c3OC)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.37
CFD P00746 1/20 0.35
KDM4E B2RXH2 5/20 0.34
MAPT P10636 4/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MAPK8 P45983 1/20 0.34
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34
PTK2 Q05397 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852490 1.00 TBXAS1 (0.37) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL23218624 0.88 ALDH1A1 (0.38) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL29852653 0.88 ALDH1A1 (0.38) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL29852955 0.87 DPP4 (0.42) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL23218076 0.87 DPP4 (0.42) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL23218279 0.83 CFD (0.41) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL29853086 0.83 CFD (0.41) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL23218583 0.82 TBXAS1 (0.39) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL29852899 0.82 TBXAS1 (0.39) TBXAS1CFDKDM4EMAPTALDH1A1
SCHEMBL29121784 0.79 TBXAS1 (0.40) TBXAS1CFDKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 CN disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 TBXAS1 2084/4885CFD 3529/4885KDM4E 851/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885CFD 1/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885CFD 1/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.